Loading market information…
JPX · 4521.T · JPY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
Kaken Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 13.84% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Kaken Pharmaceutical Co., Ltd.’s forward annual dividend is ¥190 per share, paid semi-annual. The forward yield is 4.96% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Kaken Pharmaceutical Co., Ltd.’s next earnings report is currently expected on Nov 9, 2026, with estimated earnings per share of -¥5. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Kaken Pharmaceutical Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Kaken Pharmaceutical Co., Ltd. is involved in the development, manufacturing, and commercialization of a diverse range of medical goods, health devices, and agricultural chemicals, serving both domestic and global markets. Their extensive product portfolio includes specialized treatments like Clenafin, a topical solution for fungal nail infections; Artz, an agent combating osteoarthritis; Seprafilm, an absorbable film preventing surgical adhesions; Fiblast, a spray designed for pressure and skin ulcer healing; Regroth for periodontal tissue regeneration; and Hernicore, which addresses lumbar disc herniation. They also market Adofeed, a plaster for pain and inflammation relief; Ebrantil for dysuria and hypertension management; Procylin, an oral prostaglandin I2 analogue; Lipidil, used to treat high cholesterol; Mentax, an anti-fungal cream; and Loxoprofen Na Tape, another pain-relieving and anti-inflammatory patch. Additionally, Ropion is offered as an injectable pain medication. The company's agricultural and animal health division provides products such as Polyoxins, a fungicidal agent; Pentoxazone, a herbicide for rice crops; and Salinomycin, an anti-coccidial feed additive for poultry. Kaken Pharmaceutical is actively advancing several investigational compounds. BBI-4000 has completed its Phase III clinical trials for primary axillary hyperhidrosis, while KMW-1 is also in Phase III for managing eschar removal in thermal burns. KAR is being developed for hide lice infestation, and KP-607 is currently in Phase II for the treatment of onychomycosis. Beyond pharmaceuticals, the firm also manages the rental of the commercial property, Bunkyo Green Court. Its products are sold under various brand names, including Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia. The company holds licensing agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Established in 1917, Kaken Pharmaceutical Co., Ltd. has its main office situated in Tokyo, Japan.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:19 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q3 2025 | Feb 6, 2025 | ¥129 | ¥24.62B |
|---|
| Q2 2025 | Nov 8, 2024 | ¥331 | ¥33.12B |
|---|
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
